Thrombolysis in Pulmonary Embolism: A Debatable Indication

Summary

Successfully utilized contemporary pulmonary embolism thrombolysis reverses right heart failure rapidly and safely. This therapeutic approach may lower mortality from pulmonary embolism and reduce morbidity from chronic pulmonary hypertension. Pulmonary embolism thrombolysis remains a debatable indication because large clinical trials using survival as an endpoint have not been carried out. Instead, thrombolysis trials have been undertaken with surrogate endpoints such as reduction in clot burden, reduction in pulmonary arterial pressure, and improvement in right ventricular function. In an era where hundreds of thousands of myocardial infarction patients have participated in thrombolysis trials that focus on survival as the principal endpoint, the much smaller trials of PE thrombolysis have not been sufficiently definitive to achieve a consensus. Pharmaceutical companies have not considered this area of investigation to be a good return on investment, because PE is a much less common problem than acute coronary syndromes. No government funding agency has targeted PE thrombolysis as a priority for clinical research.

Currently, the only contemporary thrombolytic regimen for pulmonary embolism that is approved by the Food and Drug Administration is tissue plasminogen activator, in a dose of 100 mg/2 h. New thrombolytic agents under development for pulmonary embolism include reteplase, saruplase, and recombinant staphylokinase. Future clinical trials will require multicenter collaboration and focus on clinically relevant endpoints such as reduction of mortality and recurrent venous thromboembolism.

Key words

Pulmonary embolism - thrombolysis

• References

• 1 Goldhaber SZ. A contemporary approach to thrombolytic therapy for pulmonary embolism. Vasc Med 2000; 5: 115-23.
• 2 Cannon CP, Goldhaber SZ. Cardiovascular risk stratification of pulmonary embolism in patients. Am J Cardiol 1996; 78: 1149-51.
• 3 Goldhaber SZ, Visani L, De Rosa M. for ICOPER.. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-9.
• 4 Kasper W, Konstantinides S, Geibel A, Tiode N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77: 346-9.
• 5 Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: Right ventricular dysfunction as predictor of mortality. Am Heart J 1997; 134: 479-87.
• 6 Jerjes-Sanchez C, Ramirez-Rivera A, Garcia M, de L, Arriaga-Nava R, Valencia S, Rosado-Buzzo A. et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. J Thromb Thrombolysis 1995; 2: 227-9.
• 7 Grifoni S, Olivotto I, Cecchini P, Pieralli F, Camaiti A, Santoro G. et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000; 101: 2817-22.
• 8 Konstantinides S, Geibel A, Kasper W, Olschewski M, Blumel L, Just H. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation 1998; 97: 1946-51.
• 9 Chartier L, Bera J, Delomez M, Asseman P, Beregi JP, Bauchart JJ. et al. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients. Circulation 1999; 99: 2779-83.
• 10 Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. Circulation 1999; 99: 1325-30.
• 11 Pacouret G, Schellenberg F, Hamel E, Charbonnier B, Mouray H. Troponin I in massive acute pulmonary embolism: results of a prospective series (letter). Presse Med 1998; 27: 1627.
• 12 Giannitsis E, Muller-Bardorff M, Kurowski V, Weidtmann B, Wiegand U, Kampmann M. et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000; 102: 211-7.
• 13 Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI. et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-5.
• 14 Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD. et al. Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry. J Am Coll Cardiol 1997; 30: 1165-71.
• 15 Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K. et al. Impact of thrombolytic treatment on the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a Multicenter Registry. Circulation 1997; 96: 882-8.
• 16 The Urokinase Pulmonary Embolism Trial.. A national cooperative study. Circulation 1973; 47: II-1-108.
• 17 Urokinase-Streptokinase Embolism Trial.. Phase 2 results. A cooperative study. JAMA 1974; 229: 1606-13.
• 18 Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980; 303: 842-5.
• 19 Sharma GVRK, Folland ED, McIntyre KM, Sasahara AA. Long-term benefit of thrombolytic therapy in patients with pulmonary embolism. Vasc Med 2000; 5: 91-5.
• 20 Dalla-Volta S, Palla A, Santolicandro A. et al. PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicenter Study 2. J Am Coll Cardiol 1992; 20: 520-6.
• 21 Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL. et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-11.
• 22 Nass N, McConnell MV, Goldhaber SZ, Chyu S, Solomon SD. Recovery of regional right ventricular function after thrombolysis for pulmonary embolism. Am J Cardiol 1999; 83: 804-6.
• 23 Parker JA, Drum DE, Feldstein ML, Goldhaber SZ. Lung scan evaluation of thrombolytic therapy for pulmonary embolism. J Nucl Med 1995; 36: 364-8.
• 24 Daniels LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80: 184-8.
• 25 Kanter DS, Mikkola KM, Patel SR, Parker JA, Goldhaber SZ. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111: 1241-5.
• 26 Meyer G, Gisselbrecht M, Diehl JL, Journois D, Sors H. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 1998; 105: 472-7.
• 27 Goldhaber SZ, Vaughan DE, Markis JE, Selwyn AP, Meyerovitz MF, Loscalzo J. et al. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986; 2: 886-9.
• 28 Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GVRK, Dawley D. et al. A randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; 2: 293-8.
• 29 Goldhaber SZ, Kessler CM, Heit JA, Elliott CG, Friedenberg WR, Heisselman DE. et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: A randomized controlled multicenter trial. J Am Coll Cardiol 1992; 20: 24-30.
• 30 Goldhaber SZ, Agnelli G, Levine MN. on behalf of the Bolus Alteplase Pulmonary Embolism Group.. Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. Chest 1994; 106: 718-24.
• 31 Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Increasing age is a major risk factor for hemorrhagic complications following pulmonary embolism thrombolysis. Am Heart J 1997; 134: 69-72.
• 32 Verstraete M, Miller GAH, Bounameaux H, Charbonnier B, Colle JP, Lecorf G. et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77: 353-60.
• 33 Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Similarity in presentation and response to thrombolysis among women and men with pulmonary embolism. J Thromb Thrombolysis 1998; 5: 95-100.
• 34 Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Attentuation over 24 hours of the efficacy of pulmonary embolism thrombolysis among cancer patients. Am Heart J 1997; 134: 603-7.
• 35 Meneveau N, Schiele F, Metz D, Valette B, Attali P, Vuillemenot A. et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemo-dynamic outcome and one-year follow-up. J Am Coll Cardiol 1998; 31: 1057-63.
• 36 Tebbe U, Graf A, Kamke W, Zahn R, Forycki F, Kratzsch G. et al. Hemo-dynamic effects of double bolus reteplase versus alteplase infusion in a massive pulmonary embolism. Am Heart J 1999; 138: 39-44.
• 37 Pacouret G, Barnes SJ, Hopkins G, Charbonnier B. Rapid haemodynamic improvement following saruplase in recent massive pulmonary embolism. Thromb Haemost 1998; 79: 264-7.
• 38 Delcroix M, Vanderschueren S, Mortelmans L, De Groof M, Herregods MC, Verhaeghe R. et al. Recombinant staphylokinase thrombolysis in patients with acute pulmonary embolism. Am J Respir Crit Care Med 1998; 157: 768a (abstr.).
• 39 Rosenschein U, Furman V, Kerner E, Fabian I, Bernheim J, Eshel Y. Ultrasound imaging-guided noninvasive ultrasound thrombolysis: preclinical results. Circulation 2000; 102: 238-45.